LEXINGTON, Ky. (May 13, 2022) — Nearly three decades after first discovering the tumor-suppressing Par-4 “super gene” that has been shown to kill cancer cells, a team of researchers at the University of Kentucky Markey Cancer Center is now learning about its role in preventing obesity – a disease that affects more than 1.9 billion people worldwide.
Vivek Rangnekar, Ph.D., associate director of the UK Markey Cancer Center and the Alfred Cohen Chair in Oncology Research, first discovered Par-4 and its role in cell death in prostate tissue in 1993. Since then, subsequent studies revealed that Par-4 is a tumor suppressor and that increased expression of Par-4 prevents tumor growth. Rangnekar and his team also found that “super mice” genetically engineered to overexpress Par-4 were resistant to cancer.
In addition to Par-4’s role in cancer suppression, recent research published by Rangnekar’s team in Frontiers in Oncology has uncovered a new role for Par-4 as a predictor of future obesity in men and women. The study shows that lack of Par-4 in mice led to increased fat absorption and fat accumulation in fat-storing cells (adipocytes), which resulted in the development of obesity. These mice also had secondary health issues, including fatty liver and insulin resistance, which are commonly associated with obesity. However, genetically restoring the missing Par-4 gene reversed the obesity, making the mice lean again.
Interestingly, mice with the same diet and physical activity as normal mice, but that lacked Par-4, still became obese.
“This finding is reminiscent of people who find it difficult to control their weight even when they are monitoring their diet or performing sufficient exercise,” Rangnekar said. “In such situations, our research indicates that there may be a genetic explanation.”
Additionally, the study shows that Par-4 loss may serve as a predictor for individuals who could be at-risk for developing obesity later in life. In collaboration with the UK Center for Clinical and Translational Science (CCTS) and Lund University in Sweden, these researchers also found that lower expression of Par-4 was associated with obesity in men and women.
“The risk of developing obesity is significantly greater in individuals who have low Par-4 levels compared to those who have high Par-4 levels,” Rangnekar said. “Our work reveals a novel function of the tumor suppressor Par-4 in regulating obesity and significantly advances the fields of adipocyte biology, physiology and metabolism.”
Future research is looking into treatment strategies that may be useful to overcome obesity and inhibit obesity-associated cancer, including an ongoing clinical trial at the UK Markey Cancer Center using a drug to elevate Par-4 in cancer patients.
“The mission of the UK Center for Clinical and Translational Science (CCTS) is to bring together clinicians, researchers and communities to accelerate the translation of basic science discoveries to tangible improvements in health,” said Philip A. Kern, M.D., director of the UK CCTS. “This type of research perfectly demonstrates why multidisciplinary collaboration is key to accelerating positive health outcomes for the commonwealth of Kentucky and beyond.”
Drs. Nathália Araújo, James Sledziona, Sunil Noothi, and Ravshan Burikhanov at the UK Markey Cancer Center contributed equally to this multidisciplinary research that involved scientists and clinicians from UK, and several other institutions in the United States and Sweden.
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA177558, the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001998, and the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P30GM127211. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers." We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.